We have a broad and differentiated clinical pipeline of multiple product candidates, each for multiple indications. Our focus is on clinically validated targets and biomarkers, and we believe that our proprietary clinical programs are well-suited for a precision-medicine approach. Our pipeline also includes two partnered clinical-stage programs.
We target some of the largest epithelial cancer indications, such as colorectal, lung, brain, breast, pancreatic and head and neck cancers, with the potential to expand into other indications and earlier lines of treatment.
The two partnered clinical-stage programs are an immuno-oncology program of six targets being developed in collaboration with Shire, one of which – a PD-1 antagonist – is in Phase 1 development, and a program directed to Staphylococcus aureus bacteremia, which is in Phase 1b development by Genentech.
In addition to our clinical trials, we maintain extensive proprietary and partnered discovery and preclinical activities to continue to realize the potential of our mAb mixture platform, and we anticipate to file additional INDs in 2018.
What are antibodies?
Antibodies are Y-shaped proteins produced by specialized cells of the body’s immune system. Antibodies can identify and bind disease-specific antigens found on bacteria, viruses, and cancer cells. Once attached to the antigen, antibodies can recruit other parts of the immune system to help neutralize the cells containing the antigen. The place on the antigen where the antibody binds is called an epitope. Researchers can design antibodies to target a certain antigen. Antibodies can be made in large amounts known as monoclonal antibodies (mAbs). Monoclonal antibodies are a well-established drug class today used to treat many diseases, including cancer.